Skip to content

Midazolam and Ketamine Effect Administered Through the Nose for Sedation of Children for Dental Treatment

Efficacy, Safety and Cost-effectiveness of Intranasal Sedation With Ketamine and Midazolam in Pediatric Dentistry: a Randomized Clinical Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02447289
Acronym
NASO
Enrollment
84
Registered
2015-05-18
Start date
2015-05-21
Completion date
2016-10-18
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Child Behavior, Dental Caries

Keywords

Dental caries, Moderate sedation

Brief summary

Randomised clinical trial to test the efficacy, safety and cost-effectiveness of sedatives; masked, controlled, parallel design with three arms, phase 4.

Detailed description

About 10% of children may have behavioral problems during dental treatment, but the evidence for sedative protocols that benefit the care in pediatric dentistry are still weak. This randomized, masked, controlled, parallel design study aims to evaluate the efficacy, safety and cost-effectiveness of intranasal sedation with ketamine / midazolam in healthy children aged 2 to 6 years old. Children will be selected among those with dental decay that do not allow dental treatment to be performed, and need at least two restorations under local anesthesia and rubber dam isolation. It is estimated a preliminarily a sample of 84 children equally divided into three groups: A) Ketamine (4.0 mg / kg up to 100 mg) + midazolam (0.2 mg / kg, maximum 5 mg) intranasally; B) ketamine (4.0 mg / kg up to 100 mg) + midazolam (0.5 mg / kg, maximum 20 mg) orally; C) midazolam (1.0 mg / kg, maximum 20 mg) orally. The hypothesis is that ketamine / midazolam combination, administered intranasally, it constitutes an effective sedative regime, safe and cost-effective for use in pediatric dentistry in the public service. The primary endpoint is the behavior of the child. Secondary endpoints are: sedative administration acceptance, procedure memory and salivary cortisol levels within each intervention group. Additionally, we will evaluate: the occurrence of pain and associated changes in facial expressions with potentially painful stimuli in children sedated for dental care; caregivers and paediatric dentists' stress and perception about sedation; adverse events that occur during and after administration of sedatives; cost-effectiveness of the sedative protocols. The experimental design is planned to minimize systematic and random errors and to contribute to higher level of evidence in future systematic reviews. The outcomes of this study have potential impact on public and private health practice, and may support institutional guidelines dealing with this theme.

Interventions

DRUGIntranasal ketamine

Ketamine injectable solution in a concentration of 50.0 mg/mL administered into the nose with an atomizer; dose of 4.0 mg/kg, maximum 100.0 mg

Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg

Midazolam injectable solution in a concentration of 5.0 mg/mL administered into the nose with an atomizer; dose of 0.2 mg/kg, maximum 5.0 mg

Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine; dose of 1.0 mg/kg, maximum 20.0 mg when give as a solely agent

Sponsors

Conselho Nacional de Desenvolvimento Científico e Tecnológico
CollaboratorOTHER_GOV
Universidade Federal de Goias
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Years to 6 Years
Healthy volunteers
Yes

Inclusion criteria

* American Society of Anesthesiologists I (healthy) or II (mild and controlled systemic disease such as persistent asthma) * Small risk of airway obstruction (Mallampati less than 2 or tonsillar hypertrophy occupying less than 50% of the oropharynx) * No medical history of neurological or cognitive changes * Absence of facial deformities * Term birth * No use of drugs that may impair cognitive functions * At least two teeth with cavities without pulp involvement, requiring dental restoration under local anesthesia and rubber dam

Exclusion criteria

* Positive or definitely positive behavior (Frankl et al, 1962) in a dental treatment session conducted by the research team

Design outcomes

Primary

MeasureTime frameDescription
Child's behavior measured by an observational scaleParticipants will be followed for the duration of the dental session, an expected average of 40 minutesChildren's behavior assessed by OSUBRS (Ohio State University Behavioral Rating Scale) in digital videos recorded during the administration. Scores: 1 - quiet, 2 - cry with movement, 3 - movement without cry; 4 - struggling. Satisfactory behavior means more than 60% of score 1 during the entire appointment.

Secondary

MeasureTime frameDescription
Participants' stress according to salivary cortisolChange from baseline in the salivary cortisol at an expected average of 40 minutesOccurrence of stress during dental procedure, assessed by salivary cortisol in children, their accompanying parent and the dentist in charge; the ELISA test will determine changes in cortisol level during dental treatment
Pain measured by the FLACC Pain Assessment ToolParticipants will be followed in video files for the duration of the dental session, an expected average of 40 minutesOccurrence of pain and associated changes in body expressions with potentially painful stimuli in children sedated for dental care
Caregivers' and dentists' perceptions on sedation measured by a Visual Analogue ScaleDuring and soon after the dental sessionPerception of caregivers and dentists on sedation, through self-report
Child's perceptions on sedation through a semi-structured interviewOne week after the dental sessionChild's perception concerning the dental treatment under sedation
Acceptance of sedative administration measured by an observational scaleParticipants will be assessed for the duration of the sedative administration, an expected average of 3 minutesAcceptance of the sedative administration, assessed by OSUBRS (Ohio State University Behavioral Rating Scale) minute by minute in digital videos recorded during the administration. Scores: 1 - quiet, 2 - cry with movement, 3 - movement without cry; 4 - struggling.
Memory of the dental procedure after 24 hours measured by a validated testParticipants will be assessed for the recall of the dental procedure, at a time point of 24 hours (average) after the end of the dental procedureMemory of the dental procedure, according to test with figures validated in Brazil. Amnesia will be reported if children do not recall the figures showed after sedative administration
Adverse events during the dental procedureParticipants will be followed for the duration of the dental session, an expected average of 40 minutesOccurrence of adverse events assessed by the World SIVA tool; adverse events will be categorised into minor, sentinel and major
Post-operative adverse events24 hoursOccurrence of adverse events while child is in the recovery room and after discharge, assessed by the World SIVA tool; adverse events will be categorised into minor, sentinel and major
Cost analysisOne year and a halfCost-effectiveness of different sedation protocols according to the methodology of health technologies assessment; the cost of each intervention will be compared
Memory of the dental procedure at the immediate post-operative period measured by a validated testParticipants will be assessed for the recall of the dental procedure, at a time point of 20 minutes (average) after the end of the dental procedureMemory of the dental procedure, according to test with figures validated in Brazil. Amnesia will be reported if children do not recall the figures showed after sedative administration

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026